TipRanks

Notifications

Bluerock Residential Announces $0.1625 Dividend for Q2

Real estate investment trust Bluerock Residential Growth REIT Inc. (BRG) announced quarterly dividends on its common and preferred shares.

The company has declared a dividend of $0.1625 per share on its Class A and Class C common shares for the second quarter.  

Furthermore, Bluerock has declared a dividend of $0.4765625 per share on its 7.625% Series C Cumulative Redeemable Preferred Stock for Q2. (See Bluerock Residential stock analysis on TipRanks)

On its 7.125% Series D Cumulative Preferred Stock, Bluerock has declared a dividend of $0.4453125 per share for Q2.

The respective dividends are payable on July 2 to stockholders of record as of June 25.

On June 3, Colliers Securities analyst David Toti reiterated a Hold rating on the stock and increased the price target to $10.5 (4% upside potential) from $10.

Toti commented, “BRG, while offering solid fundamentals in resilient assets/markets, has an overlay of structural complexity (i.e. joint ventures) that may temper enthusiasm.”

The other analyst covering the stock, BTIG’s James W. Sullivan also has a Buy rating on the stock but did not assign any price target.

Shares have gained 14.2% over the past year.

Related News:
United States Steel Sells Transtar for $640M, Shares Rise 3%
Southwest Airlines Foresees Revenue Growth; Orders 34 More Boeing 737 MAX Aircraft
CareDx Acquires Transplant Hero, Shares Rise

Tags: ,
Kailas Salunkhe
Kailas has been writing stock news and analysis at TipRanks since 2021, and has worked in the financial domain in various roles since 2013. Prior to joining TipRanks, he served as an equity research analyst at Globflex Research, a quant fund, and Market Realist, an equity research firm, analyzing companies listed on the stock markets in the U.S., Europe, the Middle East, and Asia. Kailas has also worked as an equity trader, covering the U.S. stock markets, for Capstone Securities, a proprietary trading firm. Kailas' key strength lies in analyzing the pharmaceutical, biotech, and mining sectors and companies falling in their ambit. A proponent of long-term investing, he is also proficient in equity research, report writing, financial modeling, and pitch decks. Kailas believes that the law of compounding can work wonders for all investors if they ace the Marshmallow test.